Diferencia entre revisiones de «Succinylcholine»

(Created page with "==Contraindications== 1) Known hyperK (current) 2) Massive burns >10% BSA (>4dys-healed) 3) Massive crush injuries (>4dys-healed) 4) Denervation* (>4dys-...")
 
Línea 37: Línea 37:


==Source ==
==Source ==
2/06  DONALDSON (Adapted from Rosen)
2/06  DONALDSON (Adapted from Rosen)


Levitan, R. Annals of EM. Vol 45, Issue 2. Safety of succinylcholine in myasthenia gravis.  
Levitan, R. Annals of EM. Vol 45, Issue 2. Safety of succinylcholine in myasthenia gravis.  
[[Category:Drugs]]
[[Category:Drugs]]
[[Category:Airway/Resus]]

Revisión del 04:38 13 mar 2011

Contraindications

1) Known hyperK (current)

2) Massive burns >10% BSA (>4dys-healed)

3) Massive crush injuries (>4dys-healed)

4) Denervation* (>4dys-6mo)

5) Neuromuscular dz** (indefinite)

6) Intra-abdominal sepsis (>5dys-resolution)

7) Increased ICP (may use w/ defacic dose)

(From-To)

  • CVA (in particular those with residual deficits), spinal cord injury
    • ALS, MS, skeletal muscle myopathies, cholinesterase def, h/o malignant hyperthermia

-no evidence to support contraindication in penetrating eye injuries-


N.B. Myasthenia Gravis- theoretically need more succ to induce vs nondepolarizing agents which have a prolonged effect.

This is 2/2 to lack of post-synaptic receptors, i.e. succ cannot potentiate a reaction 2/2 too few receptors.

Vs. it takes few "molecules" of roc/vec to block the few remaining functioning receptors.

Overall, most practitioners tend to avoid succ in all patients with possible neuromuscular disease.


Source

2/06 DONALDSON (Adapted from Rosen)

Levitan, R. Annals of EM. Vol 45, Issue 2. Safety of succinylcholine in myasthenia gravis.